Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.
作者信息
Geyer Mark B, Manjunath Shwetha H, Evans Andrew G, Park Jae H, Davila Marco L, Cutler Corey S, Wang Xiuyan, Wang Yongzeng, Senechal Brigitte, Rivière Isabelle, Sadelain Michel, Liesveld Jane L, Brentjens Renier J
机构信息
a Department of Medicine , Memorial Sloan Kettering Cancer Center , New York City , NY , USA.
b Center for Cell Engineering , Memorial Sloan Kettering Cancer Center , New York City , NY , USA.
出版信息
Leuk Lymphoma. 2018 Jul;59(7):1717-1721. doi: 10.1080/10428194.2017.1390237. Epub 2017 Oct 18.
Abstract
摘要
相似文献
1
Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.
Leuk Lymphoma. 2018 Jul;59(7):1717-1721. doi: 10.1080/10428194.2017.1390237. Epub 2017 Oct 18.
2
CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond.
Leuk Lymphoma. 2019 May;60(5):1346-1348. doi: 10.1080/10428194.2018.1533132. Epub 2019 Jan 16.
3
Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
Leuk Lymphoma. 2019 Jun;60(6):1454-1461. doi: 10.1080/10428194.2018.1533127. Epub 2019 Feb 4.
4
Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Hematol Oncol. 2019 Dec;37(5):601-608. doi: 10.1002/hon.2672. Epub 2019 Sep 15.
5
Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Front Immunol. 2020 Aug 11;11:1985. doi: 10.3389/fimmu.2020.01985. eCollection 2020.
6
How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.
Blood. 2020 Mar 12;135(11):804-813. doi: 10.1182/blood.2019002132.
7
CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future.
Br J Haematol. 2020 Nov;191(4):617-626. doi: 10.1111/bjh.17153.
8
Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
Hematol Oncol. 2019 Dec;37(5):655-658. doi: 10.1002/hon.2682. Epub 2019 Oct 27.
9
Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors.
Cancer J. 2019 May/Jun;25(3):217-222. doi: 10.1097/PPO.0000000000000381.
10
Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
Int J Lab Hematol. 2021 Apr;43(2):250-258. doi: 10.1111/ijlh.13375. Epub 2020 Oct 28.
引用本文的文献
1
Comparison of allogeneic hematopoietic stem cell transplantation and TKI combined with chemotherapy for adult philadelphia chromosome positive acute lymphoblastic leukemia: a systematic review and meta-analysis.
Cancer Med. 2021 Dec;10(24):8741-8753. doi: 10.1002/cam4.4413. Epub 2021 Nov 11.
2
Depletion of high-content CD14 cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing.
Mol Ther Methods Clin Dev. 2021 Jul 16;22:377-387. doi: 10.1016/j.omtm.2021.06.014. eCollection 2021 Sep 10.
本文引用的文献
1
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
J Clin Oncol. 2017 Sep 10;35(26):3010-3020. doi: 10.1200/JCO.2017.72.8519. Epub 2017 Jul 17.
2
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.
J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.
3
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Blood. 2016 Mar 3;127(9):1117-27. doi: 10.1182/blood-2015-11-679134. Epub 2016 Jan 26.
4
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.
Cancer Cell. 2015 Oct 12;28(4):415-428. doi: 10.1016/j.ccell.2015.09.004.
5
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.
Sci Transl Med. 2015 Sep 2;7(303):303ra139. doi: 10.1126/scitranslmed.aac5415.
6
B-Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia: A Report of Four Cases.
Am J Clin Pathol. 2015 Aug;144(2):333-40. doi: 10.1309/AJCPXE5VMONMVLZ0.
7
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
Blood. 2015 Jul 9;126(2):203-11. doi: 10.1182/blood-2015-01-622936. Epub 2015 Mar 23.
8
Chimeric antigen receptor T cells for sustained remissions in leukemia.
N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.
9
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.
10
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.
Blood. 2013 Feb 28;121(9):1612-21. doi: 10.1182/blood-2012-09-457531. Epub 2012 Dec 17.
Zotero 插件